SRI-29329

Cat. No.: HY-123600

CAS No.: 2086809-58-5

Molecular Formula: $C_{20}H_{26}ClN_7$

Molecular Weight: 399.92

Target: CDK

Pathway: Cell Cycle/DNA Damage

Storage:

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (125.03 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.5005 mL	12.5025 mL	25.0050 mL
	5 mM	0.5001 mL	2.5005 mL	5.0010 mL
	10 mM	0.2501 mL	1.2502 mL	2.5005 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (6.25 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 2.5 mg/mL (6.25 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

SRI-29329 is a specific CLK inhibitor, with IC_{50} values of 78 nM, 16 nM and 86 nM for CLK1, CLK2 and CLK4, respectively[1].

In Vitro

SRI-29329 (compound 8) shows some modest (~5 fold) selectivity for CLK2 over CLK1 and CLK4 without significant CDK1,4,6 activity[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Yihui Shi, et al. A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore. Bioorg Med Chem Lett. 2017 Feb 1;27(3):406-412.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA